165
Participants
Start Date
December 16, 2019
Primary Completion Date
December 31, 2022
Study Completion Date
May 31, 2025
Retinal Imaging
Retinal imaging will be conducted on the Heidelberg SPECTRALIS (FDA 510k cleared) device, routinely used in clinical care in ophthalmology. Optical Coherence Tomography (OCT) and Angiography (OCT-A) sequences will be conducted, as well as a sequence examining macular pigment (MPOD).
Pupillometry
Participants will complete a task studying pupillary response to light
Contrast Sensitivity
Participants will complete a task evaluating contrast sensitivity
Neuropsychological Evaluation
Neuropsychological evaluation will be completed, including testing in domains of memory, executive function, visuospatial ability, language, processing speed. Results will be used for research purposes only.
APOE genotyping
APOE genotyping will be completed during screening to assign participants to the correct group. Results will not be shared with participants as part of the study.
blood draw
Blood will be drawn and banked for proteomic, biomarker, and GWAS analysis
Gait Assessment
Gait assessment will be conducted by trained researcher
Actigraphy
Actigraphy monitors will be worn by all participants for 2 weeks after each visit to examine physical activity, movement, and sleep patterns.
St. Anthony's Hospital, St. Petersburg
Morton Plant Hospital, Clearwater
University of Rhode Island, Kingston
Butler Hospital, Providence
BayCare Health System
OTHER
University of Rhode Island
OTHER